Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Drelon, Coralie ^a,b   Berthon, Annabel ^a,b   Ragazzon, Bruno ^c,d   Tissier, Frédérique ^c,d   Bandiera, Roberto ^e   Sahut Barnola, Isabelle ^a,b   de Joussineau, Cyrille ^a,b   Batisse Lignier, Marie ^a,b,f   Lefrançois Martinez, Anne Marie ^a,b   Bertherat, Jérôme ^c,d   Martinez, Antoine ^a,b   Val, Pierre ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b Faculté de Médecine   (France)

^c INSTITUT COCHIN   (France)

^d CNRS UMR 8104 ^*  (France)

^e INSERM   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CORTICOTROPIN; SOMATOMEDIN B; TRANSCRIPTION FACTOR GLI1; WNT PROTEIN;

ADRENAL CORTEX TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR PROMOTION;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ANIMALS; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, TRANSGENIC;

ERINACEIDAE; MUS; MUS MUSCULUS;

EID: 84865457904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044171     Document Type: Article

References (58)

1. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, et al. (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88: 711-736.
2. Zini L, Porpiglia F, Fassnacht M, (2011) Contemporary management of adrenocortical carcinoma. Eur Urol 60: 1055-1065.
3. Abiven G, Coste J, Groussin L, Anract P, Tissier F, et al. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. The Journal of clinical endocrinology and metabolism 91: 2650-2655.
4. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, et al. (2007) Prognostic parameters of metastatic adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism 92: 148-154.
5. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356: 2372-2380.
6. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657-666.
7. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, et al. (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25: 891-897.
8. Gicquel C, Raffin-Sanson M, Gaston V, Bertagna X, Plouin PF, et al. (1997) Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82: 2559-2565.
9. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, et al. (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162: 521-531.
10. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, et al. (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90: 1819-1829.
11. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, et al. (2011) beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 17: 328-336.
12. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65: 7622-7627.
13. Berthon A, Martinez A, Bertherat J, Val P, (2011) Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol 351: 87-95.
14. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, et al. (2010) Constitutive {beta}-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 19: 1561-1576.
15. Rump P, Zeegers MPA, van Essen AJ, (2005) Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis. Am J Med Genet A 136: 95-104.
16. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, et al. (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61: 6762-6767.
17. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D, (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 136: 296-303.
18. Boulle N, Logié A, Gicquel C, Perin L, Le Bouc Y, (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83: 1713-1720.
19. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, et al. (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94: 204-212.
20. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, et al. (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 93: 3524-3531.
21. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W, (1997) Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 389: 809-815.
22. Eggenschwiler J, Ludwig T, Fisher P, Leighton PA, Tilghman SM, et al. (1997) Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev 11: 3128-3142.
23. Weber MM, Fottner C, Schmidt P, Brodowski KM, Gittner K, et al. (1999) Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 140: 1537-1543.
24. Ingram WJ, Wicking CA, Grimmond SM, Forrest AR, Wainwright BJ, (2002) Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene 21: 8196-8205.
25. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, et al. (1999) Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. Embo J 18: 5931-5942.
26. Lefrancois-Martinez AM, Bertherat J, Val P, Tournaire C, Veyssiere G, et al. (2004) Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J Clin Endocrinol Metab 89: 3010-3019.
27. Val P, Jeays-Ward C, Swain A, (2006) Identification of a novel population of adrenal-like cells in the mammalian testis. Dev Biol 299: 250-256.
28. Lambert-Langlais S, Val P, Guyot S, Ragazzon B, Sahut-Barnola I, et al. (2009) A transgenic mouse line with specific Cre recombinase expression in the adrenal cortex. Mol Cell Endocrinol 300: 197-204.
29. Hu MC, Chou SJ, Huang YY, Hsu NC, Li H, et al. (1999) Tissue-specific, hormonal, and developmental regulation of SCC-LacZ expression in transgenic mice leads to adrenocortical zone characterization. Endocrinology 140: 5609-5618.
30. Bielinska M, Kiiveri S, Parviainen H, Mannisto S, Heikinheimo M, et al. (2006) Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (mustela putorius furo) and laboratory mouse. Vet Pathol 43: 97-117.
31. Romero DG, Yanes LL, de Rodriguez AF, Plonczynski MW, Welsh BL, et al. (2007) Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion. Endocrinology 148: 2644-2652.
32. King P, Paul A, Laufer E, (2009) Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc Natl Acad Sci U S A 106: 21185-21190.
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA, (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378: 785-789.
34. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, et al. (2001) IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20: 4942-4950.
35. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19: 159-170.
36. Verras M, Sun Z, (2005) Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol 19: 391-398.
37. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221-11229.
38. Papotti M, Libé R, Duregon E, Volante M, Bertherat J, et al. (2011) The Weiss Score and Beyond-histopathology for Adrenocortical Carcinoma. Horm Canc 2: 333-340.
39. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
40. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R, (2003) Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 22: 853-857.
41. Moorehead RA, Fata JE, Johnson MB, Khokha R, (2001) Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ 8: 16-29.
42. Samani AA, Yakar S, LeRoith D, Brodt P, (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47.
43. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, et al. (2005) Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307: 1976-1978. Available:http://www.ncbi.nlm.nih.gov/pubmed/15731405. Accessed 27 March 2012.
44. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, et al. (2006) Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 66: 1940-1948.
45. Hassan AB, Howell JA, (2000) Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60: 1070-1076.
46. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, et al. (2000) Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275: 28341-28344.
47. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP, (2008) Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res 68: 8788-8795.
48. Holland EC, Sonenberg N, Pandolfi PP, Thomas G, (2004) Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144.
49. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70: 4666-4675.
50. McCauley RG, Beckwith JB, Elias ER, Faerber EN, Prewitt LH Jr, et al. (1991) Benign hemorrhagic adrenocortical macrocysts in Beckwith-Wiedemann syndrome. AJR Am J Roentgenol 157: 549-552.
51. Taurin S, Sandbo N, Yau DM, Sethakorn N, Dulin NO, (2008) Phosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells. Am J Physiol Cell Physiol 294: C1169-C1174.
52. Mattos GE, Jacysyn JF, Amarante-Mendes GP, Lotfi CFP, (2011) Comparative effect of FGF2, synthetic peptides 1-28 N-POMC and ACTH on proliferation in rat adrenal cell primary cultures. Cell Tissue Res 345: 343-356.
53. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, et al. (2000) Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 60: 834-838.
54. Kim AC, Barlaskar FM, Heaton JH, Else T, Kelly VR, et al. (2009) In search of adrenocortical stem and progenitor cells. Endocr Rev 30: 241-263.
55. Laufer E, Kesper D, Vortkamp A, King P, (2012) Sonic hedgehog signaling during adrenal development. Mol Cell Endocrinol 351: 19-27.
56. Fernandez C, Tatard VM, Bertrand N, Dahmane N, (2010) Differential modulation of Sonic-hedgehog-induced cerebellar granule cell precursor proliferation by the IGF signaling network. Dev Neurosci 32: 59-70.
57. Hartmann W, Koch A, Brune H, Waha A, Schüller U, et al. (2005) Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 166: 1153-1162.
58. Hardouin SN, Guo R, Romeo P-H, Nagy A, Aubin JE, (2011) Impaired mesenchymal stem cell differentiation and osteoclastogenesis in mice deficient for Igf2-P2 transcripts. Development 138: 203-213.